ANDA 91052, held by Aurobindo Pharma USA. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 91052 (Doxycycline Hyclate), held by Aurobindo Pharma USA, was first approved by FDA on Feb 8, 2012, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 8, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 150MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Discontinued |
| Dec 2, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 2, 2016 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 2, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 4, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 25, 2012 | Supplement 1Manufacturing | Approved | None posted |
| Feb 8, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters